Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BENEMID vs COL-PROBENECID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Competitive inhibitor of renal tubular secretion of organic acids (urate, penicillin, other drugs), enhancing urate excretion and reducing serum uric acid levels. Also inhibits renal transport of weak organic acids.
Colchicine binds to tubulin, inhibiting microtubule polymerization and reducing inflammatory cell chemotaxis. Probenecid inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion and lowering serum urate levels.
Treatment of hyperuricemia associated with gout and gouty arthritis,Adjunctive therapy for penicillin and cephalosporin antibiotics to prolong their serum half-life
Treatment of gout flares,Prophylaxis of gout flares,Hyperuricemia associated with gout (probenecid component)
250 mg orally twice daily for 1 week, then 500 mg orally twice daily; maximum 2 g/day.
Each tablet contains 0.5 mg colchicine and 500 mg probenecid. For gout prophylaxis, 1 tablet orally once daily, increasing to 1 tablet twice daily if needed. For acute gout flares, 2 tablets initially, then 1 tablet every 2 hours until relief or gastrointestinal symptoms occur, with a maximum of 8 tablets per flare.
Terminal elimination half-life 6-12 hours in adults; prolonged to 12-24 hours in renal impairment or elderly; clinically significant for twice-daily dosing
Colchicine: terminal half-life 20-30 hours (up to 40-60 hours in renal impairment). Probenecid: 6-12 hours (dose-dependent, prolonged in renal disease).
Hepatic metabolism via oxidation and glucuronidation; minimal CYP450 involvement.
Colchicine is metabolized primarily by CYP3A4 and to a lesser extent by CYP2D6. Probenecid is metabolized via glucuronidation and oxidation; it inhibits renal tubular secretion of many drugs and inhibits the metabolism of some drugs.
Renal (70-80% as unchanged drug and metabolites), biliary/fecal (20-30%)
Colchicine: ~65% renal excretion as unchanged drug and metabolites; 10-20% biliary excretion. Probenecid: ~77-88% renal excretion (primarily as glucuronide conjugate); <15% biliary/fecal.
Approximately 85-95% bound primarily to albumin
Colchicine: 30-50% bound to albumin. Probenecid: 85-95% bound to albumin.
0.15-0.30 L/kg; indicates limited extravascular distribution, consistent with high protein binding and renal elimination
Colchicine: Vd 2-4 L/kg (extensive tissue distribution, high affinity for tubulin). Probenecid: Vd 0.2-0.4 L/kg (limited extravascular distribution).
Oral: >90%
Colchicine: Oral bioavailability ~50% (wide interindividual variability). Probenecid: Oral bioavailability ~100%.
Cr Cl <50 m L/min: avoid use; Cr Cl 50-90 m L/min: reduce dose by 50%.
Contraindicated in patients with Cr Cl < 50 m L/min. Use not recommended in severe renal impairment.
No specific guidelines; use with caution in severe hepatic impairment.
Avoid use in Child-Pugh class B or C due to risk of colchicine accumulation. Use with caution in mild hepatic impairment, consider reducing dose.
Not recommended for children under 2 years. For older children: 25 mg/kg/day divided every 6 hours, up to 40 mg/kg/day maximum 2 g/day.
Not recommended for use in children (safety and efficacy not established).
Start at low end of dosing range (250 mg twice daily); monitor renal function and urate levels.
Use with caution due to increased risk of renal impairment and accumulation. Start at lower doses (e.g., 1 tablet daily). Monitor renal function and for myelosuppression.
No FDA black box warning.
None
Risk of acute gouty arthritis upon initiation; use NSAIDs or colchicine prophylactically. Use with caution in patients with peptic ulcer disease, renal impairment (Cr Cl <50 m L/min), or history of uric acid calculi. May cause aplastic anemia and other blood dyscrasias. Avoid use during acute gout attack.
Fatal overdoses have been reported with colchicine; do not exceed recommended dose.,Severe toxicity can occur with concomitant use of CYP3A4 or P-glycoprotein inhibitors.,Monitor renal function; dose adjustment required in renal impairment.,Hematologic toxicity (bone marrow suppression) with probenecid.,Uric acid stone formation; ensure adequate hydration and alkalinization of urine.,Drug interactions: colchicine with statins, macrolides, antifungals; probenecid with NSAIDs, penicillins, methotrexate.
Known hypersensitivity to probenecid; use with methotrexate or other nephrotoxic agents; severe renal impairment (Cr Cl <50 m L/min); blood dyscrasias; uric acid kidney stones; children under 2 years of age.
Hypersensitivity to colchicine or probenecid,Severe renal impairment (Cr Cl <10 m L/min),Hepatic impairment (colchicine),Blood dyscrasias (probenecid),Concurrent use of P-glycoprotein or CYP3A4 strong inhibitors (e.g., clarithromycin, ketoconazole) with colchicine
Avoid high doses of aspirin or salicylate-containing foods. Maintain adequate fluid intake. No specific food restrictions but alcohol may increase serum uric acid and reduce efficacy. Avoid large doses of vitamin C (may acidify urine and increase urate stone risk).
Avoid or limit intake of high-purine foods (organ meats, anchovies, sardines, mussels, yeast extracts) as they may precipitate gout attacks. Alcohol (especially beer and spirits) increases urate production and decreases urate excretion, raising gout risk. Take with food to minimize gastrointestinal irritation.
FDA Pregnancy Category D for second and third trimesters due to risk of neonatal hemolysis and jaundice from sulfonamide component; first trimester use associated with possible neural tube defects based on animal data and limited human reports.
Pregnancy Category D (probenecid) and C (colchicine). First trimester: Colchicine associated with increased risk of chromosomal abnormalities and neural tube defects. Second and third trimesters: Probenecid may cause fetal harm including nephrotoxicity and growth restriction. Colchicine may cause fetal toxicity at high doses.
Small amounts of probenecid and sulfonamide excreted into breast milk; M/P ratio not established. Potential for hemolysis in G6PD-deficient infants, jaundice, and kernicterus in premature infants. Contraindicated in nursing mothers due to sulfonamide component.
Colchicine: M/P ratio 0.93; small amounts excreted, monitor infant for gastrointestinal effects. Probenecid: Not recommended; M/P ratio unknown; avoid due to potential renal effects in infant.
Increased renal clearance and volume of distribution in pregnancy may reduce probenecid half-life; dose adjustment based on therapeutic response and serum uric acid levels is recommended. No specific dosing guidelines; clinical judgment advised.
Colchicine: Dose may need reduction due to increased volume of distribution and decreased clearance; monitor for toxicity. Probenecid: Dose adjustment may be needed due to increased renal clearance; monitor uric acid levels.
BENEMID (probenecid) inhibits renal tubular secretion of penicillins and cephalosporins, increasing their serum levels. Use with caution in patients with G6PD deficiency due to risk of hemolytic anemia. Avoid in patients with blood dyscrasias or peptic ulcer disease. Ensure adequate hydration to prevent urate nephropathy during gout therapy.
Colchicine and probenecid combination is used for gout prophylaxis and treatment. Monitor renal function closely; probenecid is contraindicated in Cr Cl <50 m L/min. Colchicine has a narrow therapeutic index and is contraindicated in patients with hepatic or renal impairment unless dose-adjusted. Avoid concurrent use of strong CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) which increase colchicine toxicity. Probenecid inhibits tubular secretion of many drugs (e.g., penicillins, methotrexate), increasing their levels.
Take with food or milk to reduce gastrointestinal upset.,Drink plenty of fluids (at least 2 liters daily) to prevent kidney stones.,Do not take with aspirin or other salicylates as they may reduce effectiveness.,This medication may increase the effects of other drugs like penicillins and methotrexate.,Report any signs of allergic reaction, severe skin rash, or joint pain immediately.
Take with food to reduce GI upset.,Drink plenty of fluids (at least 2-3 liters daily) to prevent kidney stones.,Report unusual bruising, bleeding, or signs of infection immediately.,Avoid alcohol as it increases serum urate levels and GI irritation.,Do not use this medication during a gout flare; wait until flare resolves.,Colchicine overdose can be fatal; seek emergency care if more than prescribed dose is taken.,Probenecid may cause false-positive urine glucose test with Clinitest.
No interactions on record
"Edoxaban, a direct factor Xa inhibitor, may inhibit organic anion transporters (OATs) involved in the renal excretion of probenecid, leading to increased probenecid plasma concentrations. Elevated probenecid levels can enhance its uricosuric effect and potentially increase the risk of adverse effects such as gastrointestinal disturbances and hypersensitivity reactions. Clinicians should be aware of this interaction when coadministering these agents, particularly in patients with renal impairment."
"Acemetacin, a nonsteroidal anti-inflammatory drug (NSAID) and prodrug of indomethacin, reduces renal clearance of probenecid by inhibiting tubular secretion and possibly competing for organic anion transporters. This leads to increased plasma concentrations of probenecid, prolonging its half-life and enhancing its uricosuric effect. Clinically, this interaction may result in elevated risk of probenecid toxicity, including gastrointestinal discomfort, rash, or rare blood dyscrasias, while also potentially increasing the anti-inflammatory effects of acemetacin."
"Cilostazol, a phosphodiesterase III inhibitor, can inhibit the renal tubular secretion of probenecid, a uricosuric agent, thereby decreasing its clearance and increasing its serum concentration. This elevation may potentiate the effects and toxicity of probenecid, including an increased risk of uric acid nephropathy and gastrointestinal disturbances. The interaction is of particular concern in patients with renal impairment or those receiving concurrent nephrotoxic drugs."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BENEMID vs COL-PROBENECID, answered by our medical review team.
BENEMID is a Uricosuric Agent that works by Competitive inhibitor of renal tubular secretion of organic acids (urate, penicillin, other drugs), enhancing urate excretion and reducing serum uric acid levels. Also inhibits renal transport of weak organic acids.. COL-PROBENECID is a Uricosuric that works by Colchicine binds to tubulin, inhibiting microtubule polymerization and reducing inflammatory cell chemotaxis. Probenecid inhibits renal tubular reabsorption of uric acid, increasing uric acid excretion and lowering serum urate levels.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BENEMID and COL-PROBENECID depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BENEMID is: 250 mg orally twice daily for 1 week, then 500 mg orally twice daily; maximum 2 g/day.. The standard adult dose of COL-PROBENECID is: Each tablet contains 0.5 mg colchicine and 500 mg probenecid. For gout prophylaxis, 1 tablet orally once daily, increasing to 1 tablet twice daily if needed. For acute gout flares, 2 tablets initially, then 1 tablet every 2 hours until relief or gastrointestinal symptoms occur, with a maximum of 8 tablets per flare.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BENEMID and COL-PROBENECID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BENEMID is classified as Category C. FDA Pregnancy Category D for second and third trimesters due to risk of neonatal hemolysis and jaundice from sulfonamide component; first trimester use associated with possible neu. COL-PROBENECID is classified as Category A/B. Pregnancy Category D (probenecid) and C (colchicine). First trimester: Colchicine associated with increased risk of chromosomal abnormalities and neural tube defects. Second and th. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.